Systems Drug Discovery for Diffuse Large B Cell Lymphoma Based on Pathogenic Molecular Mechanism via Big Data Mining...

Area of Science:

• Oncology
• Systems Biology
• Bioinformatics

Background:

• Diffuse Large B Cell Lymphoma (DLBCL) is an aggressive cancer with distinct subtypes.
• Understanding the molecular pathogenesis of DLBCL subtypes, specifically germinal center B-cell (GCB) and activated B-cell (ABC) types, is crucial for targeted therapies.

Purpose of the Study:

• To construct and identify genome-wide genetic and epigenetic networks (GWGENs) for DLBCL ABC and DLBCL GCB subtypes.
• To identify pathogenic biomarkers and potential drug targets for each DLBCL subtype.
• To discover novel drug combinations for treating DLBCL ABC and DLBCL GCB.

Main Methods:

• Genome-wide microarray data analysis for DLBCL subtypes.
• System identification and model order selection to determine real GWGENs.
• Principal Network Projection (PNP) for core network extraction.
• Deep neural network (DNN)-based drug-target interaction (DTI) modeling.

Main Results:

• Identification of subtype-specific core GWGENs for DLBCL ABC and DLBCL GCB.
• Discovery of pathogenic biomarkers serving as potential drug targets.
• Prediction of novel drug candidates and combinations effective against DLBCL subtypes.

Conclusions:

• The study provides a systems biology approach to understand DLBCL pathogenesis.
• Identified biomarkers and drug combinations offer promising therapeutic strategies for DLBCL ABC and DLBCL GCB.
• This research paves the way for personalized medicine in DLBCL treatment.